CSIMarket
 


Travere Therapeutics Inc   (TVTX)
Other Ticker:  
 

Travere Therapeutics Inc 's Quick Ratio

TVTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth




TVTX Quick Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 15.79 % 56.25 % 73.62 % 86.53 % 82.72 %
Y / Y Cash & cash equivalent Change -8.14 % 5.81 % 15.84 % 21.18 % 20.51 %
Quick Ratio MRQ 3.86 4.44 5.05 4.46 4.87
Overall Ranking # # # # #
Seq. Current Liabilities Change 5.25 % 4.2 % -3.72 % 9.65 % 42.03 %
Seq. Cash & cash equivalent Change -8.47 % -8.32 % 9.14 % 0.31 % 5.43 %



Quick Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 3.86 above Travere Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry Travere Therapeutics Inc booked the highest Quick Ratio than Travere Therapeutics Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are TVTX Segments?
See Quick Ratio TVTX on the trailing twelve month basis
Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Quick Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Travere Therapeutics Inc 's Current Liabilities $ 131 Millions Visit TVTX's Balance sheet
Travere Therapeutics Inc 's Cash & cash equivalent $ 506 Millions Visit TVTX's Balance sheet
Source of TVTX's Sales Visit TVTX's Sales by Geography


Cumulative Travere Therapeutics Inc 's Quick Ratio

TVTX's Quick Ratio for the trailling 12 Months

TVTX Quick Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 15.79 % 56.25 % 73.62 % 86.53 % 82.72 %
Y / Y Cash & cash equivalent TTM Growth -8.14 % 5.81 % 15.84 % 21.18 % 20.51 %
Quick Ratio TTM 4.44 4.7 5.11 5.57 6.25
Total Ranking TTM # 301 # 825 # 773 # 480 # 204
Seq. Current Liabilities TTM Growth 5.25 % 4.2 % -3.72 % 9.65 % 42.03 %
Seq. Cash & cash equivalent TTM Growth -8.47 % -8.32 % 9.14 % 0.31 % 5.43 %


TTM Quick Ratio Comment
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $131.03 millions, average cumulative Quick Ratio decreased to 4.44 below the Travere Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 118 other companies have achieved higher Quick Ratio than Travere Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. 301.

Explain Quick Ratio?
What are TVTX Segments?
See Quick Ratio TVTX on the trailing twelve month basis

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 119
Healthcare Sector # 204
Within the Market # 301


TTM Quick Ratio Statistics
High Average Low
6 4.21 1.57
(Mar 31 2021)   (Dec. 30, 2015)




Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2022 MRQ Cash & cash equivalentSep 30 2022 MRQ Current Liabilities
Biomea Fusion Inc   10.60 $ 133.458  Millions$ 12.589  Millions
Igm Biosciences Inc   10.55 $ 469.139  Millions$ 44.484  Millions
Tonix Pharmaceuticals Holding Corp   10.49 $ 139.978  Millions$ 13.340  Millions
Eledon Pharmaceuticals Inc   10.49 $ 65.889  Millions$ 6.280  Millions
Rhythm Pharmaceuticals inc   10.43 $ 347.795  Millions$ 33.354  Millions
Pyxis Oncology Inc   10.40 $ 198.538  Millions$ 19.095  Millions
Genprex Inc   10.38 $ 25.516  Millions$ 2.457  Millions
Sio Gene Therapies Inc   10.32 $ 49.865  Millions$ 4.830  Millions
Indaptus Therapeutics Inc   10.23 $ 28.460  Millions$ 2.782  Millions
Aadi Bioscience Inc   10.23 $ 183.007  Millions$ 17.891  Millions
United Therapeutics Corporation  10.23 $ 2,615.600  Millions$ 255.800  Millions
Rocket Pharmaceuticals Inc   10.16 $ 306.534  Millions$ 30.181  Millions
Context Therapeutics Inc   10.02 $ 39.427  Millions$ 3.933  Millions
Entrada Therapeutics Inc   10.00 $ 215.572  Millions$ 21.551  Millions
Chinook Therapeutics Inc   9.97 $ 373.283  Millions$ 37.426  Millions
Bioxcel Therapeutics Inc   9.94 $ 232.314  Millions$ 23.378  Millions
Satsuma Pharmaceuticals Inc   9.93 $ 64.436  Millions$ 6.486  Millions
Magenta Therapeutics Inc   9.93 $ 128.284  Millions$ 12.921  Millions
Reviva Pharmaceuticals Holdings Inc   9.88 $ 23.192  Millions$ 2.348  Millions
Salarius Pharmaceuticals inc   9.80 $ 16.820  Millions$ 1.717  Millions
Prothena Corporation Public Limited Company  9.80 $ 495.628  Millions$ 50.598  Millions
Shattuck Labs Inc   9.67 $ 185.114  Millions$ 19.139  Millions
Avidity Biosciences Inc   9.51 $ 405.548  Millions$ 42.666  Millions
Longboard Pharmaceuticals Inc   9.48 $ 77.319  Millions$ 8.153  Millions
Mirati Therapeutics Inc   9.46 $ 1,200.992  Millions$ 126.986  Millions
Oncternal Therapeutics Inc   9.41 $ 70.628  Millions$ 7.504  Millions
Acasti Pharma Inc   9.35 $ 34.940  Millions$ 3.735  Millions
Enanta Pharmaceuticals Inc  9.25 $ 249.232  Millions$ 26.936  Millions
Corcept Therapeutics Inc  9.21 $ 346.019  Millions$ 37.590  Millions
Hoth Therapeutics Inc   9.19 $ 9.266  Millions$ 1.008  Millions

Date modified: 2022-10-28T16:01:35+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HP's Profile

Stock Price

HP's Financials

Business Description

Fundamentals

Charts & Quotes

HP's News

Suppliers

HP's Competitors

Customers & Markets

Economic Indicators

HP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071